TrialInternational journal of cancer2026

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.

Yi-Long Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.